<DOC>
	<DOCNO>NCT00790023</DOCNO>
	<brief_summary>To demonstrate efficacy ciclesonide HFA apply nasal aerosol ( 160 μg 80 μg ) daily compare placebo subject SAR .</brief_summary>
	<brief_title>Clinical Trial Assess Efficacy Safety Ciclesonide Hydrofluoroalkane ( HFA ) Nasal Aerosol Treatment Seasonal Allergic Rhinitis</brief_title>
	<detailed_description>This randomize , double blind , placebo control , parallel group , multicenter study demonstrate efficacy ciclesonide HFA apply nasal aerosol ( 160 μg 80 μg ) daily compare placebo subject SAR . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Give write informed consent , include privacy authorization well adherence concomitant medication withhold period , prior participation . Male female 12 year old , Screening Visit ( Visit 1 ) . Subject must general good health ( define absence clinically relevant abnormality determine Investigator ) base screen physical examination , medical history , clinical laboratory value ( Hematology , Chemistries Urinalysis ) . A history SAR Mountain Cedar minimum two year immediately precede study Screening Visit ( Visit 1 ) . The SAR must sufficient severity require treatment ( either continuous intermittent ) past Investigator 's judgment ( exposure allergen ) expect require treatment throughout entire study period . A demonstrated sensitivity Mountain Cedar know induce SAR standard skin prick test administer Visit 1 ( screen ) . A positive test define wheal diameter least 5 mm large control wheal ( normal saline ) skin prick test . Subject , female 65 year age young , must negative serum pregnancy test ( perform Visit 1 ) prior randomization Visit 2 . Women childbearing potential ( exclude female least two year postmenopausal surgically sterile ) must sign Women Childbearing Potential Addendum inform consent form . Females childbearing potential must instruct agree avoid pregnancy study must use acceptable method birth control : 1 . An oral contraceptive , intrauterine device ( IUD ) , implantable contraceptive , transdermal injectable contraceptive least 1 month prior enter study continue use throughout study thirty day follow study participation . 2 . Barrier method contraception , eg , condom and/or diaphragm spermicide participate study . 3 . Abstinence . Subject parent/guardian must possess educational level degree understand English enables communicate suitably Investigator study coordinator well accurately complete AR diary RQLQ ( S ) . Female subject pregnant lactating . History physical finding nasal pathology , include nasal polyp clinically significant respiratory tract malformation ; recent nasal biopsy ; nasal trauma ; nasal ulcer perforation ; surgery atrophic rhinitis rhinitis medicamentosa ( within last 60 day prior Screening Visit ) . Participation investigational drug trial within 30 day precede Screening Visit ( Visit 1 ) plan participation another investigational drug trial time trial . A known hypersensitivity corticosteroid excipients formulation ciclesonide . History respiratory infection disorder [ include , limited bronchitis , pneumonia , chronic sinusitis , influenza , severe acute respiratory syndrome ( SARS ) ] within 14 day precede Screening Visit ( Visit 1 ) . History alcohol drug abuse ( positive urine drug screen Visit 1 ) within two year precede Screening Visit . History positive test HIV , hepatitis B hepatitis C. Plans travel outside study area ( know pollen area investigative site ) 24 hour Run period . Plans travel outside study area ( know pollen area investigative site ) 2 consecutive day Randomization Visit ( Visit 3 ) final Treatment Visit ( Visit 5 ) . Active asthma require treatment inhale systemic corticosteroid and/or routine use beta agonist controller drug ( e.g. , theophylline , leukotriene antagonist , etc . ) ; intermittent use ( less equal 3 us per week ) inhale short act betaagonists acceptable . Use prohibit concomitant medication within prescribe ( per protocol ) time period prior Screening Visit expect use treatment period . Use antibiotic therapy acute condition within 14 day prior Screening Visit . Low dose antibiotic take prophylaxis permitted therapy start prior Screening Visit expect continue throughout trial . Initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior Screening Visit use stable ( maintenance ) dose ( 30 day ) may consider inclusion . Previous participation intranasal ciclesonide HFA nasal aerosol study . Nonvaccinated exposure active infection , chickenpox measles within 21 day precede Screening Visit . Use topical corticosteroid concentration excess 1 % hydrocortisone equivalent within 30 day prior Visit 2 ; use topical hydrocortisone equivalent concentration cover great 20 % body surface ; presence underlying condition ( judged investigator ) reasonably expect require treatment preparation course study . Initiation pimecrolimus cream 1 % great tacrolimus ointment 0.03 % great study period plan dose escalation study period . However , initiation creams/ointments 30 day prior Visit 1 use stable ( maintenance ) dose study period may consider inclusion . Study participation clinical investigator site employee and/or immediate relative . Study participation one subject household time . Have follow condition judge investigator clinically significant and/or affect subject 's ability participate clinical trial : impaired hepatic function include alcoholrelated liver disease cirrhosis ; history ocular disturbance e.g . glaucoma posterior subcapsular cataract ; systemic infection ; hematological , hepatic , renal , endocrine ( except control diabetes mellitus postmenopausal symptom hypothyroidism ) ; gastrointestinal disease ; malignancy ( exclude basal cell carcinoma ) ; current neuropsychological condition without drug therapy . Any condition , judgment investigator , would preclude subject complete protocol capture assessment write .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>SAR</keyword>
</DOC>